Loading...
IXICO plc
IXI.L•LSE
Healthcare
Biotechnology
£13.00
£0.75(6.12%)
IXICO plc (IXI.L) Financial Performance & Income Statement Overview
Analyze IXICO plc (IXI.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Revenue Growth
-13.49%
↓ 13.49%
Operating Income Growth
-49.90%
↓ 49.90%
Net Income Growth
-69.86%
↓ 69.86%
Operating Cash Flow Growth
-673.51%
↓ 673.51%
Operating Margin
-46.46%
↓ 46.46%
Gross Margin
44.76%
↑ 44.76%
Net Profit Margin
-34.70%
↓ 34.70%
ROE
-20.52%
↓ 20.52%
ROIC
-27.87%
↓ 27.87%
IXICO plc (IXI.L) Income Statement & Financial Overview
Review IXICO plc IXI.L income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $3.23M | $2.54M | $3.46M | $3.20M |
| Cost of Revenue | $1.67M | $1.52M | $1.89M | $1.93M |
| Gross Profit | $1.56M | $1.02M | $1.57M | $1.27M |
| Gross Profit Ratio | $0.48 | $0.40 | $0.45 | $0.40 |
| R&D Expenses | $714000.00 | $623000.00 | $461000.00 | $464000.00 |
| SG&A Expenses | $1.94M | $2.24M | $1.84M | $1.90M |
| Operating Expenses | $2.65M | $2.61M | $2.30M | $2.36M |
| Total Costs & Expenses | -$4.32M | $4.13M | $4.19M | $4.29M |
| Interest Income | $30000.00 | $55000.00 | $61000.00 | $44000.00 |
| Interest Expense | $14000.00 | $11000.00 | $14000.00 | $15000.00 |
| Depreciation & Amortization | $234000.00 | $241000.00 | $320000.00 | $305000.00 |
| EBITDA | -$302000.00 | -$1.35M | -$143000.00 | -$564000.00 |
| EBITDA Ratio | -$0.09 | -$0.53 | -$0.12 | -$0.24 |
| Operating Income | -$1.09M | -$1.59M | -$728000.00 | -$1.09M |
| Operating Income Ratio | -$0.34 | -$0.63 | -$0.21 | -$0.34 |
| Other Income/Expenses (Net) | $541000.00 | $44000.00 | $47000.00 | $29000.00 |
| Income Before Tax | -$550000.00 | -$1.54M | -$477000.00 | -$884000.00 |
| Income Before Tax Ratio | -$0.17 | -$0.61 | -$0.14 | -$0.28 |
| Income Tax Expense | $38000.00 | -$131000.00 | -$24000.00 | -$159000.00 |
| Net Income | -$588000.00 | -$1.41M | -$453000.00 | -$725000.00 |
| Net Income Ratio | -$0.18 | -$0.56 | -$0.13 | -$0.23 |
| EPS | -$0.01 | -$0.03 | -$0.009 | -$0.01 |
| Diluted EPS | -$0.01 | -$0.03 | -$0.009 | -$0.01 |
| Weighted Avg Shares Outstanding | $48.35M | $48.35M | $48.35M | $48.27M |
| Weighted Avg Shares Outstanding (Diluted) | $48.35M | $48.35M | $48.35M | $48.27M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan